AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 APR 18 - (NewsRx.com & NewsRx.net) -- AltaRex Corp. (AXO) announced new, highly positive and consistent results from its ongoing analysis of its OvaRex phase IIb trial in metastatic ovarian cancer by taking into account predefined prognostic factors for early relapse.
The company believes that the results of this phase IIb trial, when combined with four additional prospective trials and retrospective data from a total of over 500 OvaRex treated patients will support approval on an accelerated basis.
The new overall, North American phase IIb trial analyses consider eight predefined prognostic factors as well as the level of CA125 on initiation of treatment (as identified in the earlier interim analysis).
Under this predefined analysis plan, the company reviewed results from patients receiving at least one dose of study drug as well as patients receiving at least three doses. The overall results are highly statistically significant when taking into account these predefined prognostic factors prior to and upon initiation of treatment and number of doses
Simultaneous with the analyses of the lead trial, the company has been aggressively pursuing an equity financing to afford enough time for many ...
Source: HighBeam Research, New OvaRex phase IIb yields positive results, AltaRex reports.(Brief...